Skip to main content
TipRanks
Go Ultimate75% OFF

NEUCA S.A. (NEU) AI Stock Analysis

4 Followers
PL:NEU

NEUCA S.A.

(Warsaw:NEU)

Select Model
Rating:61Neutral
Price Target:PLN 755.00▲(6.64% Upside)
Action:initiatedcoverage
Date:09/16/25

The overall stock score reflects NEUCA S.A.’s steady growth and prudent capital structure, balanced against weak net profitability and recent negative trends in cash flow. Valuation and technical analysis signals are neutral to slightly cautious, reinforcing a moderate risk-reward outlook. There are no new insights from earnings calls or corporate events that would meaningfully alter the risk profile.

Positive Factors
Stable MarginsStable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.
Negative Factors
Earnings GrowthNegative EPS growth reflects challenges in maintaining earnings momentum, which could impact NEUCA's ability to reinvest in its business and sustain shareholder returns.

NEUCA S.A. (NEU) vs. SPDR S&P 500 ETF (SPY)

-20%-15%-10%-5%0%5%10%15%20%PL:NEU-7.40%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
PLN 3.24B
Dividend Yield
2.53%
Average Volume (3M)
4,738
Price to Earnings (P/E)
16.3
Beta (1Y)
0.44
Revenue Growth
8.42%
EPS Growth
43.47%
Country
PL
Employees
5,004
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

NEUCA S.A. Business Overview & Revenue Model

Company Description

NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribut...

How the Company Makes Money

NEUCA generates revenue through several key streams. The primary source of income comes from the wholesale distribution of pharmaceuticals, which involves purchasing drugs from manufacturers and selling them to pharmacies and healthcare facilities. T...

NEUCA S.A. Financial Statement Overview

Summary

NEUCA S.A. shows stable revenue growth (TTM growth 1.8%) and a conservative balance sheet with a healthy equity ratio and improving leverage. However, persistent low net profit margins (~1%), a decline in ROE, and significant volatility culminating in negative free cash flow in the most recent period raise notable concerns about sustainable profitability and operational cash efficiency.

Income Statement

71Positive

Balance Sheet

76Positive

Cash Flow

50Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue14.14B13.64B12.61B11.81B11.23B9.86B
Gross Profit1.64B1.56B1.44B1.31B1.24B1.02B
EBITDA433.22M360.38M417.85M401.82M353.41M294.45M
Net Income196.51M155.58M154.24M146.27M137.24M150.66M
Balance Sheet
Total Assets6.23B6.33B5.51B5.18B4.84B4.12B
Cash, Cash Equivalents and Short-Term Investments137.31M168.62M143.94M119.55M225.87M89.18M
Total Debt797.46M853.32M448.57M663.43M378.08M176.59M
Total Liabilities4.90B5.06B4.10B4.12B3.91B3.23B
Stockholders Equity1.12B1.06B1.14B990.36M880.24M847.29M
Cash Flow
Free Cash Flow231.35M371.66M-29.68M194.09M254.49M247.45M
Operating Cash Flow360.91M496.54M63.23M288.27M335.94M300.20M
Investing Cash Flow-281.59M-323.45M-198.10M-257.03M-180.22M-145.49M
Financing Cash Flow-119.54M-144.95M139.62M-139.09M-6.64M-112.76M

NEUCA S.A. Technical Analysis

Technical Analysis SentimentNeutral
Last Price708.00

Price Trends

50DMA714.84Negative
100DMA732.01Negative
200DMA720.97Negative

Market Momentum

MACD-5.48Negative
RSI50.46Neutral
STOCH59.14Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:NEU, the sentiment is Neutral. The current price of 708.00 is above the 20-day moving average (MA) of 698.95, below the 50-day MA of 714.84, and below the 200-day MA of 720.97, indicating a neutral trend. The MACD of -5.48 indicates Negative momentum. The RSI at 50.46 is Neutral, neither overbought nor oversold. The STOCH value of 59.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PL:NEU.

NEUCA S.A. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PL:NEU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PL:NEUPL:NEU61NeutralPLN 3.24B16.3218.10%2.53%8.42%43.47%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PL:BIOPL:BIO45NeutralPLN 293.66M-24.89-1.97%―-15.67%-307.60%
PL:CLNPL:CLN42NeutralPLN 861.51M7.6124.89%―――
PL:MABPL:MAB41NeutralPLN 163.56M-2.89-124.37%―56.67%12.68%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%PL:NEUPL:SVEPL:CLNPL:BIOPL:MRCPL:MABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PL:NEU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PL:NEUNEUCA S.A.708.00-50.71-6.68%
PL:SVEBiomed-Lublin Wytwornia Surowic i Szczepionek S.A.2.84-1.17-29.09%
PL:CLNCelon Pharma SA15.80-5.65-26.34%
PL:BIOBIOTON S.A.3.44-0.57-14.34%
PL:MRCMercator Medical SA57.5019.1049.74%
PL:MABMabion SA10.322.7436.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2025